Converge Bio is revolutionizing biotechnology by developing advanced AI tools to enhance large language models (LLMs) for antibody research, securing $5.5 million in funding to further their innovative data enrichment processes and improve drug discovery and diagnostics. The company focuses on creating user-friendly, explainable AI models that integrate comprehensive data, addressing the complexities of biological data and regulatory requirements while aiming to become a leading provider in the biotech AI market.